Navigation Links
FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
Date:12/10/2007

New class of ApoA-I/HDL drugs to reverse atherosclerosis enters the clinic

TSX Exchange Symbol: RVX

CALGARY, Dec. 10 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that it has received approval by the US Food and Drug Administration (FDA) to initiate a Phase 1a clinical trial of oral RVX-208 in the USA. RVX-208 is a novel first-in-class small molecule that increases the production of ApoA-I and HDL. ApoA-I is regarded as the critical cardioprotective protein for the treatment of cardiovascular diseases.

The Phase I clinical trial is taking place at a leading US contract research organization. The trial consist of three arms, an ascending single dose, a fed and fasted dose effect study, and a 7-day ascending multiple dose that will enroll a total of 70-80 healthy volunteers. The primary objective of the trial is to evaluate oral RVX-208 in healthy adult subjects for safety, tolerability, and pharmacokinetics. Results from this Phase 1a trial will be used for optimizing dosing for future trials including our Phase 1b trial.

Gregory S. Wagner, PhD, Senior Vice President, Preclinical Development of Resverlogix, stated that, "RVX-208 possesses a very favorable pharmacological and pharmaceutical profile. This compound is an excellent choice to be the first drug candidate from our preclinical pipeline, our research and development team has worked aggressively to rapidly advance it into clinical development."

"This field has been developing for 50 years. In multiple human and animal studies over-expression or repeated infusion of ApoA-I inhibit progression and induce regression of atherosclerosis in both animals and humans," stated Dr. Jan Johansson, MD, PhD. Senior Vice President of Clinical Affairs of Resverlogix. "We have identified a way to increase the endogenous production of ApoA-I via a small molecule drug. The initiation of this clinical trial is a milestone for the fi
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Mirus Bio Awarded Grants & Contracts of Over $5 Million
2. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. NIH grants $750,000 to develop device to determine temperature of neonates brain
5. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
6. Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis
7. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
8. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
9. NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance
10. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
11. Resverlogix is Presenting at IAS HDL Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Sept. 18, 2014 About POCT ... performed outside a clinical laboratory. It helps in ... appropriate treatments and medication. POCT is gaining popularity ... lifestyle diseases such as diabetes, heart disease, and ... devices are standardized to minimize errors during the ...
(Date:9/18/2014)... 18, 2014 A novel robotic system ... scanner is currently being tested as part of a ... in Boston with the aim of determining if the ... prostate cancer biopsies faster, more accurate, less costly, and ... has the potential to deliver prostate cancer therapies with ...
(Date:9/18/2014)... DUBLIN, Ireland , September 18, ... ,Research and Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) ... "Biocompatible Materials - Global Strategic ... offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report ... Materials in US$ Million by the ...
(Date:9/18/2014)... 2014 On Tuesday, Secretary of Energy ... Risch for National Lab Day on the Hill. The ... national laboratory system. Durbin and Risch also formally launched ... awareness of the reach of the national labs as ... address some of our nation's most pressing challenges. , ...
Breaking Biology Technology:POCT Market in China 2014-2018 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 2Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 3
... May 12 , - ... HIT Solutions,can use CPMRC,s Interdisciplinary Clinical Content Through TSG,s ... Center (CPMRC) and The Shams Group (TSG) have partnered ... documentation that integrates with their current health,information systems. , ...
... Danish research may have come up with an explanation as ... rocks. This explanation could turn out to be the first ... with the intent of increasing oil production from Danish oil ... of the Institute of Chemistry at University of Copenhagen has ...
... N.J., May 11 Sanofi-aventis U.S. announced today that ... U.S. commercial rights to Oforta(TM) (fludarabine phosphate film-coated tablets), ... Oforta is currently approved in the United States ... with B-cell CLL. "We are extremely pleased to ...
Cached Biology Technology:CPM Resource Center and The Shams Group Partner To Help Hospitals Integrate Evidence-Based Clinical Content Into Information Systems 2CPM Resource Center and The Shams Group Partner To Help Hospitals Integrate Evidence-Based Clinical Content Into Information Systems 3CPM Resource Center and The Shams Group Partner To Help Hospitals Integrate Evidence-Based Clinical Content Into Information Systems 4New Danish research shows how oil gets stuck underground 2Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment 2Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment 3
(Date:9/19/2014)... researchers from several Harvard University labs in collaboration ... aspiring researchers with the intellectual raw materials needed ... soft, flexible materials. , With the advent of ... in manufacturing technology, soft robotics is emerging as ... conventional rigid robot design, but working with pliable ...
(Date:9/19/2014)... Imagine you are a species which over thousands of years ... exposed to a substance that makes the cold dangerous for ... Enchytraeus albidus , and the cold provoking substance, called ... cosmetics. , Nonylphenol is suspected of being a endocrine disruptor, ... It inhibits the worm,s ability to protect the cells in ...
(Date:9/18/2014)... GSA Bulletin study uses tree rings to ... Chaco Wash in northern New Mexico, USA. By determining ... willow, investigators were able to precisely date arroyo sedimentary ... this data with aerial imagery, LiDAR, longitudinal profiles, and ... , Arroyos are deep, oversized channels that have vertical ...
Breaking Biology News(10 mins):Soft robotics 'toolkit' features everything a robot-maker needs 2Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3Tree rings and arroyos 2Tree rings and arroyos 3Tree rings and arroyos 4Tree rings and arroyos 5Tree rings and arroyos 6Tree rings and arroyos 7
... of 10 new cancer drugs successfully clear preclinical ... clinical testing. A new partnership facilitated by SAIC-Frederick ... The partnership brings together The UC Davis Cancer ... Institute,s (NCI) Center for Advanced Preclinical Research (CAPR), ...
... from Germany, Malaysia, Vietnam, the Philippines, the UK, Bulgaria ... LEGATO, which will be launched on June 14, 2011, ... and Ecological Engineering Assessment Tools for risks and ... to advance long-term sustainable development of irrigated rice fields, ...
... huge plume of sulphur dioxide that spewed from Chile,s Puyehue-Cordn ... km south of Santiago. After lying dormant for more ... beginnings of this major volcanic eruption. On 4 June, a ... gas over 10 km high. ,Several thousand people were evacuated ...
Cached Biology News:NCI partners with Jackson Laboratory, UC Davis to speed cancer clinical trials 2NCI partners with Jackson Laboratory, UC Davis to speed cancer clinical trials 3LEGATO -- a major international project on sustainable development of rice ecosystems in Southeast Asia 2
Cell Culture Flask, 175 cm, tissue-culture treated polystyrene, barcoded...
... an aqueous solution that contains a purified ... a PBS buffer (phosphate buffered saline), pH ... a combination of 0.02% methylisothiazolone and 0.02% ... Stabilizer provides optimum performance for both microsphere ...
... clone K28/86.2, PDZ Domain GenBank ... : GST fusion to residues 77-299 ... Tris pH 7.4, 0.075M NaCl containing ... evaluated by immunoblot on rat brain ...
... The ProteoPrep 20 Plasma Immunodepletion Kit ... proteins from human plasma or serum in ... enables deeper penetration into the plasma proteome ... single or multidimensional chromatography or go straight ...
Biology Products: